17199-38-1 Usage
Molecular weight
143.18 g/mol The mass of one mole of 1-AMINO-3-METHYLCYCLOPENTANECARBOXYLIC ACID is 143.18 grams.
Structure
Cyclopentane ring with a carboxylic acid and an amino group The compound has a five-carbon ring structure with a carboxyl group (-COOH) and an amino group (-NH2) attached at different positions on the ring.
Position of functional groups
1-AMINO-3-METHYL The amino group is attached to the first carbon of the cyclopentane ring, and the methyl group is attached to the third carbon.
Potential applications
Pharmaceutical and drug design Due to its unique molecular structure, this compound may be used in the development of new drugs and medications.
Use as a building block
Organic synthesis 1-AMINO-3-METHYLCYCLOPENTANECARBOXYLIC ACID can be used to create more complex molecules in organic chemistry.
Research interest
Chemistry and biochemistry The properties and uses of this compound continue to be of interest to researchers in the fields of chemistry and biochemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 17199-38-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,1,9 and 9 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 17199-38:
(7*1)+(6*7)+(5*1)+(4*9)+(3*9)+(2*3)+(1*8)=131
131 % 10 = 1
So 17199-38-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H13NO2/c1-5-2-3-7(8,4-5)6(9)10/h5H,2-4,8H2,1H3,(H,9,10)
17199-38-1Relevant articles and documents
2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
-
Page/Page column 98; 99, (2021/06/26)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.
